Roche sheds Lowe as Xenical agency

Goetzl, David; Snyder Bulik, Beth
April 2000
Advertising Age;4/17/2000, Vol. 71 Issue 17, p1
Trade Publication
This article reports on the decision of Hoffman-La Roche to replace the Lowe Group as the advertising agency for weight loss drug Xenical in April 2000. The account for Xenical includes an estimated $80 million direct-to-consumer business as well as physician-targeted advertising. One hurdle Xenical's marketer faces is that the drug may be best known among consumers for its potential side effects. Furthermore, the U.S. Food and Drug Administration requires that marketers include fair balance information about a drug's potential negatives in any design-to-cost advertisement that tout a drug's specific benefits. Xenical generated $140 million in U.S. sales in nine months last year according to IMS Health.


Related Articles

  • FIRST CANADIAN TRIAL FOR XENICAL LAUNCHED.  // Worldwide Biotech;Mar2001, Vol. 13 Issue 3, p5 

    Reports that Hoffman-La Roche Limited has initiated a clinical trial to evaluate its weight loss medication Xenical in Canada.

  • Orlistat approved.  // Healthy Weight Journal;Sep/Oct1999, Vol. 13 Issue 5, p66 

    Reports on the approval of the drug orlistat from Roche Laboratories for the treatment of obesity. Efficacy of the drug; Side effects of the drug.

  • Obesity drugs trim ads. Goetzl, David // Advertising Age;8/13/2001, Vol. 72 Issue 33, p10 

    The article reports on the decision of obesity drug manufacturers Hoffmann-La Roche and Abbott Pharmaceuticals to discontinue direct-to-consumer (DTC) advertising for their products. Hoffmann-La Roche's new campaign, launched in February 2001, which was designed in part to divert attention from...

  • Roche Kicks Off Review for Xenical. McMains, Andrew // Adweek Midwest Edition;04/17/2000, Vol. 41 Issue 16, p86 

    Reports the launching of a review of Xenical account by Roche Laboratories company. Estimated budget for the account; Reason for the decline in sales of the drug.

  • Xenical account moves to Y&R.  // Medical Marketing & Media;Aug2000, Vol. 35 Issue 8, p24 

    Reports that Hoffmann-La Roche has moved its account for Xenical to Y&R Advertising. Previous handling of the account by Lowe Consumer Healthcare; Awarding of the first professional promotion for Xenical to Sudler and Hennessey.

  • Xenical ads lack balance.  // Healthy Weight Journal;May/Jun2000, Vol. 14 Issue 3, p35 

    Deals with the letter made by the United States Food and Drug Administration (FDA) to Hoffman-LaRoche Inc. on the television advertisement of its Xenical or orlistat drug. FDA complaint on the advertisement's imbalances; Action taken by the company on the complaint.

  • Roche Kicks Off Review for Xenical Fat Drug. McMains, Andrew // Adweek Eastern Edition;4/17/2000, Vol. 41 Issue 16, p4 

    Reports on Roche Laboratories has launched a review of the Xenical account at Lowe Consumer Healthcare. Creative and media duties in play; Potential side effects of Xenical.

  • Lowe holds onto Xenical on the 2nd time around. Gleason, Mark; Hodges, Jane // Advertising Age;12/2/1996, Vol. 67 Issue 49, p8 

    This article reports on the selection of Lowe & Partners/SMS of New York by Roche Laboratories to handle the launch of its anti-obesity prescription drug, Xenical, in 1996. This account costs $45 million. However, for Lieber, Levett, Koenig, Farese & Babcock, Roche's decision is a setback. Roche...

  • Xenical endures ad silence as FDA forces alterations. Goetzl, David // Advertising Age;11/8/1999, Vol. 70 Issue 46, p40 

    This article reports on the changes made by U.S. drug company Hoffmann-La Roche to the direct-to-consumer advertising campaign for its obesity drug Xenical as of November 1999. The U.S. Food and Drug Administration (FDA) charged the commercial, valued at $70 million to $75 million, lacked fair...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics